1. Pink Sheet
  2. >>Geography

EMA’s Cancer ‘Pathfinder’ Project Targets Conditional Approvals, Endpoints & RWE

 
• By Ian Schofield

This second of a two-part article on the EU’s “Cancer Medicines Pathfinder” initiative looks at the trade-off between the benefits and risks of conditional drug approvals and differing perceptions of progression-free survival as a validated endpoint in cancer drug trials.

Cancer Diagnosis and disease detection or screening as a treatment for malignant cells with a biopsy or testing with a cancerous cell as an immunotherapy symbol
The EMA is targeting the development of drugs for cancer • Source: Shutterstock

Among the aims of the European Medicines Agency’s “Cancer Medicines Pathfinder” initiative are to gauge how far regulators are willing to accept the uncertainties associated with the EU’s conditional marketing authorization system, and to contribute to the ongoing debate over the use of endpoints in cancer treatment.

Also in the pipeline is a study to garner views on the use of real-world evidence in approval applications for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Elevidys Helps Sarepta To First US FDA Platform Technology Designation

 
• By Bridget Silverman

Sarepta's rAAVrh74 vector, used in the marketed Duchenne muscular dystrophy gene therapy Elevidys and across the company's limb girdle muscular dystrophy pipeline, earned a platform designation as the lead LGMD candidate prepares for BLA filing.

Pink Sheet Podcast: The US and Ex-US Impact Of Most-Favored Nation Drug Pricing

 
• By Derrick Gingery, Francesca Bruce, Cathy Kelly, and Nielsen Hobbs

Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.